血清scd25测定在肝细胞癌诊断中意义-significance of serum scd 25 in diagnosis of hepatocellular carcinoma.docxVIP

摘要在刺激时，就会导致体内免疫系统的紊乱，肿瘤细胞就会以各种方式破坏免疫系统, 发挥免疫逃避机制 [14]。sCD25 产生于白介素-2(interleukin-2, IL-2)受体的 膜相关 α 亚基的溶蛋白裂解。机体受到刺激时， 细胞免疫激活，T 细胞活化， 活化后的 T 细胞分泌 IL-2，同时 IL-2 是 T 细胞活化和增殖重要的细胞因子，活 化后的 T 细胞 IL-2R 的表达增加、脱落增加 [15]。研究表明, 血液系统恶性肿瘤、 乳腺癌及结肠癌等恶性肿瘤中血清 sCD25 水平明显升高, 且与肿瘤负荷、早期 复发具有相关性[10]。国内有关 sCD25 在 HCC 患者血清中表达的研究较少。目的探讨血清 sCD25 水平在肝细胞癌(hepatocellular carcinoma, HCC)诊断中的意 义。方法本实验包括 160 例研究对象: 40 例 HCC; 40 例 LC; 40 例慢乙肝, 40 例健康对 照。通过酶联免疫吸附方法(enzyme-linked immune sorbent assay,ELISA)测定所有 研究对象血清中 sCD25 水平。结果HCC 组血清 sCD25 水平(均值= 9641.23 pg/ml)高于 LC 组、慢乙肝组及对照 组(P0.05)。sCD25 比甲胎蛋白(Alpha Fetal Protein ,AFP)诊断 HCC 的敏感性高。结论本实验表明，sCD25（95%CI:7584.47-11697.99 pg/ml）比甲胎蛋白(Alpha Fetal Protein ,AFP) 诊断早期 HCC 的敏感性更高。有可能作为早期 HCC 监测的方法。关键词：sCD25；肝细胞癌；肝硬化；慢乙肝IIThe significance of serum sCD25 level in the diagnosis of hepatocellular carcinomaPostgraduateGuo Huimin SupervisorLi JianshengDepartment of Gastroenterology, First Affiliated Hospital of Zhengzhou University Zhengzhou Henan 450052, ChinaAbstractBackgroundPrimary liver cancer (Primary liver cancer, PLC) mainly includes two histopathological types: hepatocellular carcinoma (hepatocellular carcinoma, HCC) and intrahepatic bile duct carcinoma (intrahepatic cholangiocarcinoma, ICC), they differ from each other significantly in pathogenesis, biological behavior and histologic morphology, clinical manifestation, treatment and prognosis. Since HCC accounted for more than 90% of primary liver cancer, so we took the HCC patients as the main research object in this paper. Hepatocellular carcinoma (HCC) accounts for the third most common cause of death from neoplasm in the world, with an ever increasing incidence expected in the next ten years. It is hard to diagnose the disease at the onset, because it is mild with no signs or symptoms at early stage. The disease progresses vary fast; most of the patients had already reached locally advanced or distant metastasis at the time of diagnosis, which lead to treatment difficulty and poor prognosis, and